Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04709276
Title A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Andrew J. Armstrong, MD

prostate adenocarcinoma

prostate carcinoma

prostate cancer

prostate neuroendocrine neoplasm

prostate small cell carcinoma


Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.